Renalytix Plc ADR (RNLX) concluded trading on Thursday at a closing price of $0.54, with 4.72 million shares of worth about $2.55 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.66% during that period and on Thursday the price saw a gain of about 96.87%. Currently the company’s common shares owned by public are about 46.89M shares, out of which, 46.30M shares are available for trading.
However, the stock later moved at a day high price of 0.5480, or with a gain of 96.87%. Stock saw a price change of 80.53% in past 5 days and over the past one month there was a price change of 34.34%. Year-to-date (YTD), RNLX shares are showing a performance of 38.82% which decreased to -82.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $4.04 during that period. The average intraday trading volume for Renalytix Plc ADR shares is 200.02K. The stock is currently trading 79.03% above its 20-day simple moving average (SMA20), while that difference is up 45.06% for SMA50 and it goes to -68.10% lower than SMA200.
Renalytix Plc ADR (NASDAQ: RNLX) currently have 46.89M outstanding shares and institutions hold larger chunk of about 17.31% of that.
The stock has a current market capitalization of $27.05M and its 3Y-monthly beta is at 2.10. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 1.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNLX, volatility over the week remained 32.79% while standing at 16.95% over the month.
Analysts are in expectations that Renalytix Plc ADR (RNLX) stock would likely to be making an EPS of -$0.09 in the current quarter, while forecast for next quarter EPS is -$0.08 and it is -$0.27 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.09 which is -$0.09 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.28 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 32.75% while it is estimated to increase by 29.72% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on January 18, 2022 offering a Buy rating for the stock and assigned a target price of $30 to it.
